Media Spend Trends: Changing Lanes - Pharmaceutical Executive


Media Spend Trends: Changing Lanes
You've got their attention—now what? Marketing analysts predict a spending shift from branded direct-to-consumer efforts to more disease awareness and corporate reputation promotions.

Pharmaceutical Executive

Catching Interest, Resisting Involvement Although marketers may struggle with keeping patients on treatment, there are signs they're getting better at generating initial, pre-prescription interest. TV continues to be the crown jewel of this effort, with DTC ad awareness levels jumping from 69 to 89 percent between 2003 and 2004. Sue Ramspacher, senior vice president of NOP World Health, says TV's triumph is directly related to a "dramatic spend" by marketers in this medium. Spending rose from $1.9 billion in 2003 to $2.6 billion in 2004.

Patrick Burns
"In early 2004 you couldn't turn on the TV without seeing ads for the newest erectile dysfunction drugs, and the COX-2 wars were still going on," Ramspacher says.

"Believability" of DTC ads, according to Ramspacher, rose to 57 percent across all media channels, as did "likeability," which rose to 66 percent in categories like asthma.

In spite of this good news, she says DTC promotion is still preaching to the choir rather than gathering new converts: "DTC primarily influences patients who are already diagnosed and are being treated, but fails to motivate the undiagnosed and untreated who represent more than 50 percent of sufferers in many large categories."

Elizabeth Boehm
Such was the case with Eli Lilly's osteoporosis medication, Evista (raloxifene), according to Jay Bolling, managing partner of Roska Direct. "We had a well-defined audience, but the product was not on their radar screen," says Bolling. "Women would see an ad for Evista and think of their mother, not of themselves. In cases like this, you're dealing with issues of apathy and denial."

Bolling and his team launched an ad campaign in women's books which included a consumer response vehicle that wove together product and disease awareness information. It offered a 30-day free trial offer for Evista to women who redeemed a certificate included in the mail-in response.

Moving Right Along There are various reasons why people who would benefit from a prescription resist taking it.

"Some people may be suffering but, whether they be internal beliefs or barriers, don't think they're ready for a medication," Ramspacher says. "When these people see a branded prescription drug ad, they ignore it because they're not seeing themselves in them. This speaks to the need for pharmaceutical marketers to better balance their branded message ads and their unbranded disease awareness ads." Some companies are already experimenting with this more subtle awareness-to-adoption mix and are reaping early successes.

COX-2 Effect?
Consumers may rush straight to the doctor after seeing a drug ad, but they are rushing to the computer to find out more. NOP figures suggest that the Internet is becoming the "intermediary" between doctors and patients; nearly one-third of those who contacted their doctors after seeing a DTC ad first went to the web to find out more. (See "Reaching Consumers Online.")

As the relatively new field of DTC advertising matures, it is becoming increasingly clear to marketers that effective consumer messages operate on a continuum of action; it's up to them to prod consumers almost every step of the way. Indeed, even if a consumer is motivated enough to go to their doctor and get a prescription, 25 percent never make it to the pharmacy. "Getting to the doctor is one thing, taking a drug is another," Boehm quips.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here